Methotrexate for Crohn's Disease: A Patient's 2026 Guide

If you have been told by your gastroenterologist that methotrexate for Crohn's disease might be a good option for you, you are far from alone. For over three decades, methotrexate has helped people with Crohn's taper off steroids and maintain remission - and the 2025 AGA Living Guideline has reaffirmed its place in the treatment toolkit (4). This guide walks through what methotrexate does, what the evidence says, how to take it safely, and how it compares to other treatments in 2026.

Key Takeaways

• In the landmark 1995 NEJM trial, 39.4% of steroid-dependent Crohn's patients on methotrexate reached remission at 16 weeks versus 19.1% on placebo (1)
• The 2025 AGA Living Guideline recommends subcutaneous or intramuscular methotrexate over no treatment for moderate-to-severe Crohn's and specifically recommends against oral methotrexate monotherapy (4)
• Daily folic acid supplementation (typically 1 mg) is standard alongside methotrexate to reduce nausea, mouth sores, and fatigue without blunting its therapeutic benefit (6)
• Methotrexate is strictly contraindicated in pregnancy because it is teratogenic - reliable contraception is essential for patients and their partners (4, 6)
• Methotrexate takes 8 to 12 weeks to show meaningful benefit, so patience and consistent weekly dosing are key

What Is Methotrexate and How It Works in Crohn's Disease

Methotrexate is an immunomodulator - a medication that dampens the overactive immune signaling that drives inflammation in Crohn's disease. Unlike biologics such as infliximab or adalimumab, which target a single specific protein, methotrexate works more broadly on immune cell activity. It is a prescription medication that should only be started, dosed, and monitored by a gastroenterologist.

Methotrexate as an immunomodulator

At the low doses used in Crohn's disease (far lower than those used in cancer treatment), methotrexate reduces inflammation by interfering with folate-dependent pathways that immune cells rely on to multiply and send inflammatory signals. This is why folic acid supplementation is paired with it - more on that in a dedicated section below.

When gastroenterologists use methotrexate

Gastroenterologists typically consider methotrexate in a few specific situations. It is classically used to induce and maintain remission in patients who are steroid-dependent or who cannot tolerate or have failed thiopurines like azathioprine or 6-mercaptopurine (6). In the current biologic era, it is also used as monotherapy for milder or steroid-dependent disease, or combined with a TNF inhibitor to reduce the formation of anti-drug antibodies (4).

The steroid-sparing goal

For many of us in the Crohn's community, the main appeal of methotrexate is that it can help taper off long-term corticosteroids. Chronic steroid use comes with well-documented consequences - bone loss, cataracts, weight gain, mood changes, and more. As we explored in our article on the long-term effects of steroid use, getting off steroids safely is often a top priority. Methotrexate gives many patients a realistic path to do that.

What the Evidence Shows: Efficacy in Crohn's Disease

The evidence for methotrexate in Crohn's disease rests on two landmark New England Journal of Medicine trials, a Cochrane systematic review, and several supporting studies. Here is what the numbers say.

The 1995 Feagan NEJM induction trial

In the first major double-blind, placebo-controlled trial, Feagan and colleagues randomized steroid-dependent Crohn's patients to receive intramuscular methotrexate 25 mg weekly or placebo for 16 weeks. The result: 39.4% of methotrexate patients reached clinical remission versus 19.1% on placebo (1). This was the study that established methotrexate as a genuine option for Crohn's induction.

The 2000 Feagan NEJM maintenance trial

A follow-up trial tested whether lower-dose methotrexate could keep patients in remission. Patients who had responded to induction received 15 mg weekly by intramuscular injection. At 40 weeks, 65% of methotrexate patients remained in remission compared with 39% on placebo (2). The message was clear: methotrexate was not just a short-term fix.

The 2014 Cochrane review and later studies

Patel and colleagues published a Cochrane review pooling five randomized trials with 333 patients. Their conclusion: intramuscular methotrexate 15 mg weekly is superior to placebo for maintenance of remission, with a number needed to treat of about four (3). A 2020 review by Rosh in Gastroenterology and Hepatology reported that approximately one third of adults on methotrexate maintain remission at one year, with a number needed to treat of roughly five for induction (5). In a 2014 observational study of 35 refractory Crohn's patients, 80% had a clinical response and 51.4% achieved remission (7).

It is worth being honest about the limitations. Most of the randomized data predates the biologic era, sample sizes are modest, and modern high-efficacy biologics generally show larger effect sizes than methotrexate monotherapy. But that does not erase the real benefit methotrexate offers, especially for the patients it is best suited for.

How Methotrexate Is Taken: Dosing, Route, and Timing

The way you take methotrexate matters as much as the dose itself. The 2025 AGA Living Guideline is specific on this point: it suggests subcutaneous or intramuscular methotrexate monotherapy over no treatment for moderate-to-severe Crohn's, and it suggests against oral methotrexate monotherapy for this population (4).

Subcutaneous or intramuscular over oral

Why the route preference? Above about 15 mg, parenteral dosing (injection) gives more reliable blood levels than an oral pill because oral absorption plateaus - you can swallow a higher dose without actually absorbing proportionally more (5). Subcutaneous injection using a prefilled pen or syringe is generally the most practical option, and many patients learn to self-inject at home with a quick tutorial from their care team (3).

Standard dosing during induction and maintenance

The typical approach is 25 mg once weekly by subcutaneous or intramuscular injection during induction, lasting roughly 16 to 24 weeks. If the medication works, the dose is usually reduced to 15 mg once weekly for maintenance (4, 5).

How long it takes to work

Methotrexate is not a fast-acting medication. It generally takes 8 to 12 weeks to start showing meaningful benefit, so patience is essential. Take your dose on the same day each week, keep a simple dose diary, and never take two doses close together if you miss one - contact your care team for guidance instead.

Folic Acid: A Small Pill That Makes Methotrexate Safer

One of the first things your gastroenterologist will mention alongside methotrexate is folic acid. This inexpensive supplement plays a critical role in making methotrexate more tolerable.

Why folic acid matters

Methotrexate works by blocking folate metabolism, which is part of how it dampens inflammation. But the same mechanism is why it can cause nausea, mouth sores, fatigue, and other side effects if your body's folate stores drop too low. Daily folic acid supplementation is standard alongside methotrexate, recommended by both the Crohn's & Colitis Foundation and the AGA (6). The good news: folic acid reduces gastrointestinal side effects without blunting methotrexate's benefit for Crohn's disease.

How much folic acid and when to take it

The typical dose used in IBD practice is 1 mg of folic acid orally daily, often skipping the day methotrexate is taken - though patients should follow their own clinic's protocol. If you want to understand more about why folate matters for people with Crohn's, our guide to folate deficiency in Crohn's disease covers the full picture.

Side Effects and Safety Monitoring

Like all immunomodulators, methotrexate has a side effect profile that deserves an honest discussion. Knowing what to expect makes it easier to spot problems early and manage the common nuisances.

Common side effects and how to manage them

The most frequently reported side effects include nausea (especially on injection day), fatigue, mild hair thinning, mouth ulcers, and headache (3, 5). Most of these are mild and tend to improve with folic acid supplementation or antiemetics. Some patients find that taking methotrexate in the evening or before bed helps them sleep through the worst of the nausea.

Serious risks: liver, blood counts, and infections

The main serious risks to be aware of include liver enzyme elevations (hepatotoxicity), bone marrow suppression (low white blood cell or platelet counts), and rarely, a lung inflammation called pneumonitis (5). Routine blood monitoring - including a complete blood count and liver function tests - is recommended, typically every 4 to 12 weeks depending on your clinic's protocol (4). Alcohol use should be minimized because it increases the risk of liver damage, and people with pre-existing liver disease may not be good candidates for methotrexate.

As with other immunomodulators, standard vaccinations should be up to date before starting. Live vaccines are usually avoided while on methotrexate, and any fever or unusual infection should prompt a call to your care team (6).

Pregnancy warning

This is one of the most important points in this guide. Methotrexate is teratogenic - it can cause miscarriage and serious birth defects. It is strictly contraindicated during pregnancy. Both people who could become pregnant and their partners should use reliable contraception and stop methotrexate for a period before trying to conceive, as directed by their gastroenterologist (4, 6). If you are thinking about starting a family, our pregnancy management guide covers how to plan around Crohn's medications.

How Methotrexate Compares to Other Crohn's Treatments

Where does methotrexate fit among the growing number of Crohn's treatments? The answer depends on your specific situation.

Methotrexate vs thiopurines

Azathioprine and 6-mercaptopurine (the thiopurines) are the other major immunomodulators used in Crohn's disease. The 2020 Rosh review and clinical practice suggest methotrexate is a reasonable option when thiopurines have failed or cannot be tolerated, with a broadly similar overall safety profile but a different side effect pattern (5). For example, methotrexate does not carry the same risk of pancreatitis that thiopurines do, but it does carry the pregnancy contraindication.

Methotrexate in combination with biologics

The 2025 AGA guideline recommends combining infliximab with a thiopurine over infliximab alone in thiopurine-naive patients. However, it makes no recommendation for or against combining infliximab (or non-TNF biologics) specifically with methotrexate due to limited evidence (4). In real-world practice, many gastroenterologists still add low-dose methotrexate to an anti-TNF biologic to reduce anti-drug antibody formation, especially in patients who cannot take a thiopurine.

Where methotrexate fits in 2026

Here is the honest tradeoff. Modern high-efficacy biologics and targeted small molecules - risankizumab, guselkumab, upadacitinib - generally outperform methotrexate on hard endpoints in clinical trials. But methotrexate is far less expensive, has decades of real-world safety data, and remains a genuinely useful tool for the right patient. The right choice is always individualized. For a broader look at how all the options compare, our IBD medications comparison guide lays them side by side.

The best approach is a shared decision-making conversation with your gastroenterologist that weighs disease severity, prior treatments, insurance coverage (which varies widely by country), plans for pregnancy, and your personal preferences.

Frequently Asked Questions

Is methotrexate safe for long-term use in Crohn's disease?

For many patients, yes. The 2000 Feagan maintenance trial showed sustained benefit at 40 weeks, and many gastroenterologists continue methotrexate for years with appropriate blood monitoring (2). Regular complete blood counts and liver function tests, typically every 4 to 12 weeks, are standard to catch any problems early (4).

How long does methotrexate take to work for Crohn's disease?

Methotrexate typically takes 8 to 12 weeks to show meaningful clinical benefit. This is slower than corticosteroids but expected for immunomodulators. Your gastroenterologist will likely assess your response around the 16-week mark, consistent with the induction period used in clinical trials (1).

Can I take methotrexate as a pill instead of an injection?

The 2025 AGA Living Guideline specifically suggests against oral methotrexate monotherapy for moderate-to-severe Crohn's disease because oral absorption plateaus above about 15 mg, resulting in less reliable blood levels (4, 5). Subcutaneous injection with a prefilled pen is the most common approach and can be done at home.

Can I drink alcohol while on methotrexate?

Alcohol should be minimized because both methotrexate and alcohol are processed by the liver, and combining them increases the risk of liver damage. Most gastroenterologists advise keeping alcohol consumption very low or avoiding it altogether. Discuss your specific situation with your care team.

What should I do if I want to get pregnant while on methotrexate?

Stop methotrexate and discuss timing with your gastroenterologist well before attempting conception. Methotrexate is strictly contraindicated in pregnancy because it causes miscarriage and birth defects (4, 6). Both people who could become pregnant and their partners should use reliable contraception during treatment. Our pregnancy management guide covers planning in detail.

Is methotrexate the same as chemotherapy?

Methotrexate is used in cancer treatment, but at much higher doses. The doses used for Crohn's disease - typically 15 to 25 mg weekly - are a fraction of chemotherapy doses and work by modulating the immune system rather than by killing cancer cells. The side effect profile at IBD doses is far milder than what cancer patients experience.

What should I ask my doctor about methotrexate?

Key questions include: Is subcutaneous or intramuscular dosing better for me? How often will I need blood tests? What folic acid dose should I take? When should I expect to see improvement? And if you are of reproductive age: What contraception plan should be in place, and how long before trying to conceive should I stop? These questions help ensure you and your gastroenterologist are aligned on monitoring and expectations.

References

1. Feagan, B.G., et al. Methotrexate for the treatment of Crohn's disease. New England Journal of Medicine, 1995;332(5):292-297. View on PubMed
2. Feagan, B.G., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. New England Journal of Medicine, 2000;342(22):1627-1632. View on PubMed
3. Patel, V., et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews, 2014. Read review
4. American Gastroenterological Association. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology, 2025. Read guideline
5. Rosh, J.R. The Current Role of Methotrexate in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2020;16(1). Read article
6. Guideline Central. 2025 AGA Guidelines for Pharmacologic Management of Moderate-to-Severe Crohn's Disease. 2025. Read summary
7. Xu, P., et al. The efficacy and safety of methotrexate in refractory Crohn's disease. Zhonghua Nei Ke Za Zhi, 2014;53(3):188-192. View on PubMed